이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Effect of Dietary Intervention on LDL-C and Lipoprotein Subclasses Distribution in Patients With Hypercholesterolemia

2019년 11월 4일 업데이트: Nimbe Torres y Torres, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Effect of Dietary Intervention on LDL-C Levels and Lipoprotein Subclasses Distribution in Patients With Hypercholesterolemia

The primary aim of the present study was to elucidate the effect of a combination of functional foods on the low-density lipoprotein cholesterol (LDL-C) levels and on the distribution of the lipoprotein subclasses in subjects with hypercholesterolemia. To accomplish the latter, subjects that met the inclusion criteria and had mild hypercholesterolemia (Total cholesterol >200mg/dL, and LDL-C >130mg/dL <190 mg/dL) were recruited for double-blind, parallel, controlled dietary intervention study. After two weeks of dietary standardization with an isocaloric diet, subjects were randomized and allocated to either placebo or a dietary portfolio treatment for two months. The secondary endpoints were the size of the different lipoprotein subclasses, total cholesterol levels, high density -lipoprotein cholesterol (HDL-C) levels, apolipoprotein B, triglycerides, total/HDL-C ratio, apolipoprotein B/apolipoprotein A ratio, and anthropometric measurements.

연구 개요

상세 설명

The present work took place at the Department of Physiology of Nutrition at the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ). The study followed a randomized, controlled, double-blind, parallel design encompassing five visits. On the first visit, volunteers were screened for eligibility criteria. Subjects that met the inclusion criteria were then invited to a second visit. Herein, volunteers received a thorough explanation of the experimental maneuver, as well as the overall objectives of the study. Thereafter, subjects who agreed to participate signed a consent form.

Upon agreement, assessment of habitual dietary intake and physical activity was obtained by 24-hour dietary recalls, food frequency questionnaire (FFQ), and by the International Physical Activity Questionnaire (IPAQ), respectively. Additionally, anthropometric measurements and blood samples were registered and collected. Then, volunteers underwent dietary standardization for two weeks with isocaloric diets (LSFD), which followed the National Cholesterol Education Program (NCEP) , Adult Treatment Panel III (ATP III) criteria. That is, 50-60% carbohydrates, 15% protein, 25-35% fat,<7% saturated fat,≤ 200mg of dietary cholesterol, 20-35g of fiber, and 2000mg/d of sodium.

On the third visit, subjects were randomly allocated to either LSFD plus placebo or an LSFD plus the dietary portfolio (DP). Of note, the prescribed diets were matched to the volunteers' habitual caloric intake -considering the energy provided by the placebo or DP- to avoid variability of the endpoint variables due to weight-loss. The DP and placebo provided 200kcal; the DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The organoleptic characteristics and packaging were similar between treatments. Subjects were instructed to consume two packets per day, preferably with breakfast and dinner. The content of each packet (30g of product) was dissolved in 250-300ml of water.

Volunteers followed the given treatment for two consecutive months, during which two follow-up visits took place. Blood samples, anthropometric characteristics, and blood pressure were obtained in all visits.

Compliance to diet, placebo, and DP was assessed with 24-hour dietary recalls, 3-day dietary records, and with the number of empty packets returned on the corresponding visits.

연구 유형

중재적

등록 (실제)

62

단계

  • 해당 없음

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

20년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Men and women
  • Body mass index (BMI) 25 to ≤ 39.9 kg/m2
  • Adults between 20 and 60 years of age
  • Total cholesterol levels of >200mg/dL in serum
  • LDL-C levels ≥130mg/dL ≤190mg/dL
  • Literate subjects
  • Signature of informed consent

Exclusion Criteria:

  • Subjects with diabetes
  • Diseases that produce obesity or diabetes
  • Cardiovascular events
  • Weight-loss of ≥ 3kg on the preceding months to the study
  • Catabolic diseases such as cancer and acquired immunodeficiency syndrome
  • Pregnancy and breastfeeding
  • Positive Smoking
  • Pharmacological treatment including:

Antihypertensive drugs Hypoglycemic agents Statins, fibrates or any other treatment for dyslipidemia Steroid medications Chemotherapy, immunosuppressants, and radiotherapy Anorexigens or other medication to induce weight-loss

  • Subjects with high cardiovascular risk
  • Subjects with symptomatic digestive pathologies

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: Placebo (P)
The placebo consisted of 30g of calcium caseinate, 30g of maltodextrin, and 0.2g of flavoring. The placebo was provided in a dehydrated form in a packet containing 30g each provided twice a day. The content of each packet was dissolved in 250ml of water.
A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
실험적: Dietary Portfolio (DP)
The DP included 25g of soy protein, 14g of dehydrated nopal,14g of oats, 4g of chia seeds, 4g of inulin, and 0.15g of flavoring. The DP was provided in a dehydrated form in a packet containing 30g each. The content of each packet was dissolved in 250ml of water.
A mixture of functional foods divided into 30g individual packets.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Low density lipoprotein- cholesterol (LDL-C)
기간: Change in total LDL-C after 2.5 months of treatment
Plasma total LDL-C (mg/dl)
Change in total LDL-C after 2.5 months of treatment
Lipoprotein subclasses
기간: Change in small, medium and large LDL, HDL and VLDL lipoprotein subclasses after 2.5 months of treatment
High density lipoprotein (HDL), low density lipoprotein (LDL), and very low density lipoprotein (VLDL) subclasses (small medium and large) as measure by nuclear magnetic resonance spectroscopy (NMR) in μmol/L.
Change in small, medium and large LDL, HDL and VLDL lipoprotein subclasses after 2.5 months of treatment

2차 결과 측정

결과 측정
측정값 설명
기간
Total cholesterol
기간: Change in total cholesterol after 2.5 months of treatment
Plasma total cholesterol (mg/dL)
Change in total cholesterol after 2.5 months of treatment
Triglycerides
기간: Change in triglycerides after 2.5 months of treatment
Plasma triglycerides (mg/dL)
Change in triglycerides after 2.5 months of treatment
High density lipoprotein cholesterol (HDL-C)
기간: Change after 2.5 months of treatment
Plasma HDL cholesterol (mg/dL)
Change after 2.5 months of treatment
Apolipoprotein B
기간: Change after 2.5 months of treatment
Change in apolipoprotein B in
Change after 2.5 months of treatment
Apolipoprotein A
기간: Change after 2.5 months of treatment
Change in apolipoprotein A in plasma
Change after 2.5 months of treatment
Total/ high density lipoprotein cholesterol (HDL-C) ratio
기간: Change after 2.5 months of treatment
Change in total/ high density lipoprotein cholesterol (HDL-C) ratio
Change after 2.5 months of treatment
Apolipoprotein B/Apolipoprotein A ratio
기간: Change after 2.5 months of treatment
Change in Apolipoprotein B / Apolipoprotein A ratio
Change after 2.5 months of treatment

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Nimbe Torres y Torres, PhD, INCMNSZ

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2013년 2월 28일

기본 완료 (실제)

2018년 12월 18일

연구 완료 (실제)

2018년 12월 18일

연구 등록 날짜

최초 제출

2019년 10월 31일

QC 기준을 충족하는 최초 제출

2019년 10월 31일

처음 게시됨 (실제)

2019년 11월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2019년 11월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2019년 11월 4일

마지막으로 확인됨

2019년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

Placebo에 대한 임상 시험

3
구독하다